MARC details
| 000 -LEADER |
|---|
| fixed length control field |
04615nmi a22003857a 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20210518171200.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS |
|---|
| fixed length control field |
m||||| |||| 00| 0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
c| zz uauuu |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
180124d2020 sp ||||| |||| 00| 0 spa d |
| 040 ## - CATALOGING SOURCE |
|---|
| Transcribing agency |
Salus Infirmorum |
| 100 1# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Oviedo Prada, Soraya Lola |
| 9 (RLIN) |
3530 |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
¿Es la inmunoterapia de células car-t el tratamiento definitivo de las neoplasias de células b? / |
| Statement of responsibility, etc. |
Soraya Lola Oviedo Prada; tutoras: María Miana Ortega y Patricia Rodríguez Camacho |
| Medium |
[Trabajo Fin de Grado] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Date of publication, distribution, etc. |
2020 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
1 archivo (pdf.) ; |
| Dimensions |
1,83 MB |
| 500 ## - GENERAL NOTE |
|---|
| General note |
Trabajo fin de grado. Defendido en 2020 |
| 520 3# - SUMMARY, ETC. |
|---|
| Summary, etc. |
Introducción y objetivos: la terapia de células CAR-T se considera un tipo de tratamiento inmunológico poco conocido y muy novedoso que está siendo una revolución en el mundo de la medicina moderna, por lo que el propósito de esta revisión es evaluar el impacto de la terapia CAR-T en pacientes con mal pronósticodiagnosticados de Linfoma No Hodgkin difuso de células B grandes (LBDCG) y de Leucemia Linfoblástica Aguda (LLA) de células B, ambas enfermedades refractarias o recidivantes.<br/>Material y método: en esta revisión bibliográfica la estrategia de búsqueda y la obtención de artículos se llevó a cabo desde Noviembre de 2019 hasta Marzo de 2020 a través de bases de datos como Medline/PubMed y EBSCOhost, que tras <br/>aplicar los criterios de inclusión y exclusión se seleccionaron trece artículos para elaborar el estudio.<br/>Resultados: tras la administración de la terapia CAR-T en pacientes con mal pronóstico diagnosticados de LLA de células B y LBDCG que tras varias líneas de tratamiento convencional desarrollan recidivas o son diagnosticados de enfermedad refractaria, se ha determinado una remisión completa (RC) superior al 70% post tratamiento, además de observar que los datos porcentuales de RC son muy superiores a los datos de recaída.<br/>Conclusiones: se ha demostrado que la terapia CAR-T es un tratamiento eficaz tanto por los datos reflejados de RC como por un incremento en la supervivencia en pacientes con mal pronóstico diagnosticados de LBDCG o de LLA de células B.<br/>Además, se ha determinado que los efectos adversos más frecuentes son el síndrome de liberación y citoquinas (SLC) y el síndrome neurológico asociado al tratamiento con células inmunoefectoras (ICANS). |
| 520 8# - SUMMARY, ETC. |
|---|
| Summary, etc. |
Introduction and objectives: CAR-T cell therapy is considered a little known and very novel type of immune treatment that is revolutionizing the world of modern medicine. <br/>The purpose of this review is to evaluate the impact of CAR-T therapy in patients with poor prognosis diagnosed with diffuse large B-cell Non-Hodgkin's Lymphoma (LBDCG) and Acute Lymphoblastic Leukemia (ALL), both refractory or relapsing diseases.<br/>Method: in this bibliographic review the search strategy and the obtaining of articles was carried out from November 2019 to March 2020 through databases such as Medline/PubMed and EBSCOhost, and after applying the inclusion and exclusion criteria thirteen articles were selected to prepare the study.<br/>Results: after the administration of CAR-T therapy in patients with poor prognosis diagnosed with B-cell ALL and LBDCG who after several lines of conventional treatment develop relapses or are diagnosed with refractory disease, a complete remission (CR) of more than 70% has been determined after treatment, in addition to observing that the percentage data of CR is much higher than the data of relapse.<br/>Conclusions: CAR-T therapy has been shown to be an effective treatment for both CR data and increased survival in patients with poor prognosis diagnosed with B-cell LBDCG or ALL. Furthermore, it has been determined that the most frequent adverse <br/>effects are the cytokine release syndrome (CRS) and the neurological syndrome associated with treatment with immunosuppressive cells (ICANS) |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
leucemia |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
linfoma no Hodgkin |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
terapia genética |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
inmunoterapia adoptiva |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
receptores quiméricos de antígenos |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Antígenos CD19 |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
leukemia |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
lymphoma, Non-Hodgkin |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
genetic therapy |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
immunotherapy, adoptive |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
receptors, chimeric Antigen |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
antigens, CD19 |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Miana Ortega, María |
| 9 (RLIN) |
490 |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Rodríguez Camacho, Patricia |
| 9 (RLIN) |
3524 |
| 710 2# - ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
Universidad Pontificia de Salamanca. |
| Subordinate unit |
Facultad de Enfermería y Fisioterapia Salus Infirmorum. |
| -- |
Grado en Enfermería. |
| 9 (RLIN) |
489 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Universal Decimal Classification |
| Koha item type |
TFG/TFM |
